Log in

NASDAQ:SLPSimulations Plus Stock Price, Forecast & News

$65.83
+0.75 (+1.15 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$64.36
Now: $65.83
$66.94
50-Day Range
$53.95
MA: $62.55
$72.09
52-Week Range
$26.00
Now: $65.83
$73.58
Volume295,503 shs
Average Volume310,010 shs
Market Capitalization$1.17 billion
P/E Ratio131.66
Dividend Yield0.37%
Beta-0.08
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application to organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; and RENAsym for investigating and predicting drug-induced or acute kidney injury. Further, the company provides population modeling and simulation contract research services for the pharmaceutical and biotechnology industries; and clinical-pharmacology-based consulting services in support of regulatory submissions. It sells its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies. The company was founded in 1996 and is headquartered in Lancaster, California.
Read More
Simulations Plus logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.76 out of 5 stars


Industry, Sector and Symbol

Industry Computer integrated systems design
Sub-IndustryN/A
Current SymbolNASDAQ:SLP
CUSIPN/A
Phone661-723-7723

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.97 million
Cash Flow$0.65 per share
Book Value$2.15 per share

Profitability

Net Income$8.58 million

Miscellaneous

Employees93
Market Cap$1.17 billion
Next Earnings Date11/11/2020 (Estimated)
OptionableOptionable
$65.83
+0.75 (+1.15 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SLP News and Ratings via Email

Sign-up to receive the latest news and ratings for SLP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Simulations Plus (NASDAQ:SLP) Frequently Asked Questions

How has Simulations Plus' stock been impacted by COVID-19 (Coronavirus)?

Simulations Plus' stock was trading at $30.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SLP stock has increased by 118.0% and is now trading at $65.83.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Simulations Plus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Simulations Plus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Simulations Plus
.

When is Simulations Plus' next earnings date?

Simulations Plus is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Simulations Plus
.

How were Simulations Plus' earnings last quarter?

Simulations Plus, Inc. (NASDAQ:SLP) issued its earnings results on Thursday, July, 9th. The technology company reported $0.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.06 by $0.14. The technology company earned $12.30 million during the quarter, compared to analyst estimates of $10.58 million. Simulations Plus had a return on equity of 24.44% and a net margin of 22.96%.
View Simulations Plus' earnings history
.

How often does Simulations Plus pay dividends? What is the dividend yield for Simulations Plus?

Simulations Plus declared a quarterly dividend on Thursday, July 9th. Shareholders of record on Monday, July 27th will be given a dividend of $0.06 per share on Monday, August 3rd. This represents a $0.24 annualized dividend and a yield of 0.36%. The ex-dividend date is Friday, July 24th.
View Simulations Plus' dividend history
.

What price target have analysts set for SLP?

1 equities research analysts have issued 12-month price targets for Simulations Plus' stock. Their forecasts range from $75.00 to $75.00. On average, they anticipate Simulations Plus' share price to reach $75.00 in the next year. This suggests a possible upside of 13.9% from the stock's current price.
View analysts' price targets for Simulations Plus
.

Has Simulations Plus been receiving favorable news coverage?

News coverage about SLP stock has trended very positive on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Simulations Plus earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the technology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Simulations Plus
.

Who are some of Simulations Plus' key competitors?

What other stocks do shareholders of Simulations Plus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Simulations Plus investors own include Advanced Micro Devices (AMD), Verizon Communications (VZ), AGNC Investment (AGNC), Altria Group (MO), NVIDIA (NVDA), Omega Healthcare Investors (OHI), AT&T (T), Cisco Systems (CSCO), ServiceNow (NOW) and Paypal (PYPL).

Who are Simulations Plus' key executives?

Simulations Plus' management team includes the following people:
  • Mr. Walter S. Woltosz, Co-Founder & Chairman (Age 74)
  • Mr. Shawn M. O'Connor, Chief Exec. Officer (Age 59)
  • Mr. John R. Kneisel, Chief Financial Officer (Age 61)
  • Dr. Thaddeus Henry Grasela Jr., Pharm.D., PharmD, Ph.D., Pres Buffalo Division, Director of Simulations Plus & Director (Age 65)
  • Mr. John Anthony DiBella, Pres of the Lancaster Division (Age 39)

What is Simulations Plus' stock symbol?

Simulations Plus trades on the NASDAQ under the ticker symbol "SLP."

Who are Simulations Plus' major shareholders?

Simulations Plus' stock is owned by many different institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (1.14%), Congress Asset Management Co. MA (1.10%), Mutual of America Capital Management LLC (0.59%), Principal Financial Group Inc. (0.56%), Stanley Laman Group Ltd. (0.29%) and Bessemer Group Inc. (0.29%). Company insiders that own Simulations Plus stock include David L Ralph, John Kenneth Paglia and Walter S Woltosz.
View institutional ownership trends for Simulations Plus
.

Which institutional investors are selling Simulations Plus stock?

SLP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Raymond James & Associates, Congress Asset Management Co. MA, Calamos Advisors LLC, Wedge Capital Management L L P NC, Mutual of America Capital Management LLC, Stanley Laman Group Ltd., and Alps Advisors Inc..
View insider buying and selling activity for Simulations Plus
.

Which institutional investors are buying Simulations Plus stock?

SLP stock was bought by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Foundry Partners LLC, Comerica Bank, SG Americas Securities LLC, Virtu Financial LLC, Texas Permanent School Fund, Exchange Traded Concepts LLC, and Conestoga Capital Advisors LLC.
View insider buying and selling activity for Simulations Plus
.

How do I buy shares of Simulations Plus?

Shares of SLP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Simulations Plus' stock price today?

One share of SLP stock can currently be purchased for approximately $65.83.

How big of a company is Simulations Plus?

Simulations Plus has a market capitalization of $1.17 billion and generates $33.97 million in revenue each year. The technology company earns $8.58 million in net income (profit) each year or $0.48 on an earnings per share basis. Simulations Plus employs 93 workers across the globe.

What is Simulations Plus' official website?

The official website for Simulations Plus is www.simulations-plus.com.

How can I contact Simulations Plus?

Simulations Plus' mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company can be reached via phone at 661-723-7723 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.